Nanosphere 10-Q 5 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 03, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'NSPH	'
Entity Registrant Name	'NANOSPHERE INC	'
Entity Central Index Key	'0001105184	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	117,295,106

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
CURRENT ASSETS:	'	'
Cash and cash equivalents	$12,507	$41,467
Accounts receivable - Net allowance for doubtful accounts	3,304	2,821
Inventories	10,140	8,452
Other current assets	303	248
Total current assets	26,254	52,988
PROPERTY AND EQUIPMENT- Net of accumulated depreciation	5,269	3,673
INTANGIBLE ASSETS - Net of accumulated amortization	2,161	2,406
OTHER ASSETS	206	284
TOTAL	33,890	59,351
CURRENT LIABILITIES:	'	'
Accounts payable	2,458	1,958
Accrued compensation	1,287	910
Other current liabilities	2,636	1,534
Long-term debt - current portion	3,751	2,081
Total current liabilities	10,132	6,483
LONG-TERM LIABILITIES:	'	'
Long-term debt	6,958	9,734
Total liabilities	17,090	16,217
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' EQUITY:	'	'
Common stock, $0.01 par value; 150,000,000 shares authorized; 76,895,106 issued and outstanding as of September 30, 2014, and 100,000,000 shares authorized; 76,222,606 shares issued and outstanding as of December 31, 2013	769	762
Preferred stock, $0.01 par value; 10,000,000 shares authorized; no shares issued	0	0
Additional paid-in capital	428,239	424,962
Warrants to acquire common stock	246	246
Accumulated deficit	-412,454	-382,836
Total stockholders' equity	16,800	43,134
TOTAL	$33,890	$59,351

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	150,000,000	100,000,000
Common stock, shares issued	76,895,106	76,222,606
Common stock, shares outstanding	76,895,106	76,222,606
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0

Condensed_Statements_of_Operat

Condensed Statements of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
REVENUE:	'	'	'	'
Product sales	$3,688	$2,367	$9,643	$6,588
Total revenue	3,688	2,367	9,643	6,588
COSTS AND EXPENSES:	'	'	'	'
Cost of sales	2,361	1,476	6,053	4,282
Research and development	5,534	4,992	14,705	13,985
Sales, general, and administrative	5,054	4,959	17,436	13,558
Total costs and expenses	12,949	11,427	38,194	31,825
Loss from operations	-9,261	-9,060	-28,551	-25,237
OTHER INCOME (EXPENSE):	'	'	'	'
Foreign exchange loss	-1	-2	-1	-5
Interest expense	-341	-369	-1,072	-582
Interest income	1	4	6	16
Total other expense	-341	-367	-1,067	-571
NET LOSS	($9,602)	($9,427)	($29,618)	($25,808)
Net loss per common share - basic and diluted	($0.13)	($0.16)	($0.39)	($0.45)
Weighted average number of common shares outstanding - basic and diluted	76,303	60,318	76,256	57,721

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($29,618)	($25,808)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	1,551	1,526
Amortization of financing costs, accretion of debt discount and other	241	135
Share-based compensation	2,631	1,707
Provision for doubtful accounts	89	'
Changes in operating assets and liabilities:	'	'
Accounts receivable	-572	-964
Inventories	-2,435	-2,622
Other current assets	-55	65
Accounts payable	494	-1,418
Accrued and other current liabilities	1,383	755
Net cash used in operating activities	-26,291	-26,624
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Purchases of property and equipment	-2,147	-1,041
Net cash used in investing activities	-2,147	-1,041
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from the issuance of debt	'	12,000
Debt issuance costs	'	-278
Payments on debt	-1,175	'
Proceeds from the issuance of common stock, net of offering expenses	'	32,630
Payment of noncurrent liability	'	-750
Proceeds from stock option exercise	653	188
Net cash (used in) / provided by financing activities	-522	43,790
NET (DECREASE) / INCREASE IN CASH AND CASH EQUIVALENTS	-28,960	16,125
CASH AND CASH EQUIVALENTS - Beginning of period	41,467	33,139
CASH AND CASH EQUIVALENTS - End of period	12,507	49,264
NONCASH INVESTING AND FINANCING ACTIVITIES:	'	'
Reclassification of inventory to (from) property and equipment	747	864
Capital expenditures included in accounts payable	$257	$116

Description_of_Business

Description of Business	9 Months Ended
	Sep. 30, 2014
Description of Business	'
	1. Description of Business
	Nanosphere, Inc. (the “Company”) develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, that enables simple, low cost, and highly sensitive genomic and protein testing on a single platform.
	Basis of Presentation — The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and in conformity with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, in the opinion of management, all adjustments, consisting only of normal recurring adjustments, unless otherwise noted herein, necessary to present fairly the results of operations, financial position and cash flows have been made. Therefore, these condensed financial statements should be read in conjunction with the Company’s most recent audited financial statements for the year ended December 31, 2013 and notes thereto included in the Company’s Annual Report on Form 10-K. The results of operations for any interim period are not necessarily indicative of the results of operations expected for the full year.
	The accompanying condensed financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.
	Deferred Financing Costs— Costs incurred to issue debt are deferred and amortized as a component of interest expense using the effective interest method over the term of the related debt agreement. Amortization expense of deferred financing costs began with the incurrence of the debt in May 2013 and was less than $0.1 million during the three months ended September 30, 2014 and $0.1 million for the nine months ended September 30, 2014. For 2013, deferred financing costs were less than $0.1 million during the three and nine month periods ending September 30, 2013.
	Use of Estimates — The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company’s significant estimates included in the preparation of the condensed financial statements are related to inventories, property and equipment, intangible assets and share-based compensation. Actual results could differ from those estimates.
	Fair Value of Financial Instruments — The carrying amount of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and debt approximate their fair values.
	New Accounting Pronouncements — In May 2014, the FASB issued Accounting Standards Update “ASU” No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This new guidance is effective for annual reporting periods beginning on or after December 15, 2016, including interim periods within that reporting period. Early adoption is not permitted. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements.
	In August 2014, the FASB issued ASU No.2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU explicitly requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date. Management will consider relevant conditions that are known (and reasonably knowable) at the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. Disclosures will be required if conditions give rise to substantial doubt. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Early adoption is permitted. The Company currently discloses its uncertainty about its ability to continue as a going concern. The Company does not expect the adoption of ASU No. 2014-15 to have material impact on its disclosures or its consolidated financial statement.

Liquidity_and_Capital_Resource

Liquidity and Capital Resources	9 Months Ended
	Sep. 30, 2014
Liquidity and Capital Resources	'
	2. Liquidity and Capital Resources
	As of September 30, 2014, the Company has incurred net losses attributable to common stock of $412.5 million since inception, and has funded those losses primarily through the sale and issuance of equity securities and secondarily through the issuance of debt. While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses in the foreseeable future. The Company had cash and cash equivalents of $12.5 million as of September 30, 2014 and net cash used in operating activities of $26.3 million for the nine month period ended September 30, 2014.
	In May 2013, the Company entered into a $22 million loan agreement with Silicon Valley Bank and Oxford Finance LLC and concurrently the Company drew down $12 million of the facility. The Company did not achieve the established milestones by September 30, 2014 to access the remainder of the facility and therefore the additional facility is no longer available. The Company also has entered into a Common Stock Purchase Agreement, the Purchase Agreement, with Aspire Capital Fund, LLC, or Aspire, to purchase, at the Company’s option, up to an aggregate of $30.0 million of shares of common stock over a two-year term. To date, no shares have been purchased under this agreement. See Note 10 for details on the termination of this common stock purchase agreement with Aspire.
	Management is uncertain that its current and anticipated cash resources would be sufficient to support currently forecasted operations through at least the next twelve months, and therefore, the Company will need additional debt or equity financing in the future to execute its business plan and to be able to continue as a going concern. Capital outlays and operating expenditures may increase over the next twelve months as the Company expands its infrastructure, manufacturing capacity and research and development activities to support commercialization of our products. These capital outlays and operating expenditures would be curtailed if the Company is not successful in raising additional funds. Many of the aspects of the Company’s forecasts involve management’s judgments and estimates that include factors that could be beyond our control and actual results could differ. These and other factors could cause our forecasted plans to be unsuccessful which could have a material adverse effect on our operating results, financial condition, and liquidity.

Net_Loss_Per_Common_Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2014
Net Loss Per Common Share	'
	3. Net Loss Per Common Share
	Basic and diluted net loss, per common share have been calculated in accordance with ASC Topic 260, “Earnings Per Share”, for the three and nine month periods ended September 30, 2014 and 2013. As the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same.
	The computation of basic net loss per common share for the three and nine month periods ended September 30, 2014 and 2013 excluded 592,000 and 478,250 shares of restricted stock, respectively (see Note 6). While these restricted shares of stock are included in outstanding shares on the condensed balance sheet, these restricted shares are excluded from basic net loss per common share in accordance with ASC Topic 260 due to the forfeiture provisions associated with these shares.
	The computations of diluted net loss per common share for the three and nine month periods ended September 30, 2014 and 2013 did not include the outstanding shares of restricted stock as well as the effects of the following options to acquire common stock and common stock warrants as the inclusion of these securities would have been antidilutive:
		Nine Month Periods Ended September 30,
		2014		2013
	Restricted stock		592,000		478,250
	Restricted stock units		—		220,000
	Stock options		5,362,434		6,068,489
	Common stock warrants		136,019		136,019
			6,090,453		6,902,758

Intangible_Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2014
Intangible Assets	'
	4. Intangible Assets
	Intangible assets, consisting of purchased intellectual property, as of September 30, 2014 and December 31, 2013 comprise the following (in thousands):
		September 30, 2014							December 31, 2013
		Cost		Accumulated			Net		Cost		Accumulated			Net
				Amortization							Amortization
	Intellectual property—licenses	$	3,263	$	(1,363	)	$	1,900	$	3,263	$	(1,152	)	$	2,111
	Patents		455		(194	)		261		455		(160	)		295
		$	3,718	$	(1,557	)	$	2,161	$	3,718	$	(1,312	)	$	2,406
	Amortization expense for intangible assets was $0.1 million and $0.2 million for the three and nine month periods ended September 30, 2014 and 2013, respectively. Estimated future amortization expense is as follows (in thousands):
	Years Ending December 31
	2014 (Period from October 1 to December 31)	$	81
	2015		322
	2016		309
	2017		293
	2018		211
	Thereafter		945
	Licenses are amortized from the date of initial use of the licensed technology and such amortization continues over the remaining life of the license. The future amortization expense reflected above is based on licenses for which the licensed technology is being used as of September 30, 2014.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions	'
	5. Related Party Transactions
	Dr. Chad Mirkin, a co-founder of the Company, provided contracted research and development services to the Company. The Company incurred expenses of less than $0.1 million for these services for the nine months period ended September 30, 2013. On March 27, 2013, the Company advised Dr. Mirkin that his consulting agreement would not be renewed and would expire pursuant to its terms on May 31, 2013. On April 22, 2013, Dr. Mirkin advised the Company that he would not stand for re-election to the Company’s board of directors at the 2013 annual meeting and retired from the board of directors at the expiration of his 2013 term.

Equity_Incentive_Plan

Equity Incentive Plan	9 Months Ended
	Sep. 30, 2014
Equity Incentive Plan	'
	6. Equity Incentive Plan
	The Company’s board of directors has adopted and the shareholders have approved the Nanosphere, Inc. 2000 Equity Incentive Plan (the “2000 Plan”), the Nanosphere, Inc. 2007 Long-Term Incentive Plan (the “2007 Plan”) and the Nanosphere, Inc. 2014 Long-Term Incentive Plan (the “2014 Plan,” and together with the 2000 Plan and the 2007 Plan, the “Plans”). Upon adoption of the 2014 Plan at the Company’s annual meeting of shareholders on May 28, 2014, the 2000 Plan and 2007 Plan were terminated. The Plans authorize the compensation committee to grant stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, incentive stock options, deferred share units and performance awards. Option awards are generally granted with an exercise price equal to or above the fair value of the Company’s common stock at the date of grant with ten year contractual terms. Certain options vest ratably over four years of service, while other options cliff vest after seven years of service but provide for accelerated vesting contingent upon the achievement of various company-wide performance goals, such as decreasing time to market for new products and entering into corporate collaborations (as defined in the option grant agreements). For these “accelerated vesting” options, 20-25% of the granted option shares will vest upon the achievement of each of four or five milestones as defined in the option grant agreements, with any remaining unvested options vesting on the seven year anniversary of the option grant dates. Approximately 15% of the options granted and outstanding contain “accelerated vesting” provisions. The fair values of the Company’s option awards granted during the nine month period ended September 30, 2014 were estimated at the dates of grant using the Black-Scholes option pricing model with the following assumptions:
	Expected dividend yield		0	%
	Expected volatility		78	%
	Risk free interest rate		1.78	%
	Weighted-average expected option life in years		5.51
	Estimated weighted-average fair value on the date of grant based on the above assumptions	$	0.88
	Estimated forfeiture rate for unvested options		0	%
	The expected volatility for option awards granted in 2014 was based on the Company’s actual historical volatility. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of the grants for periods consistent with the expected life of the option. The expected life of options that vest ratably over four years of service is derived from the average of the vesting period and the term of the option as defined in the Plans, following the guidance in Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin Nos. 107 and 110. The Company estimates the expected life of options with accelerated vesting terms giving consideration to the dates that the Company expects to achieve key milestones under the option agreements and the term of the option.
	Total compensation cost recognized for all stock option awards was $0.8 million and $2.6 million in the three and nine month periods ended September 30, 2014, respectively, and $0.4 million and $1.1 million for the three and nine month periods ended September 30, 2013, respectively.
	As of September 30, 2014, the total compensation cost not yet recognized related to the non-vested stock option awards is approximately $2.0 million, which is expected to be recognized over the next three years, with a weighted average term of 1.7 years. Certain milestone events are deemed probable of achievement prior to their seven year vesting term, and the acceleration of vesting resulting from the achievement of such milestone events has been factored into the weighted average vesting term. While the Company does not have a formally established policy, as a practice, the Company has delivered newly issued shares of its common stock upon the exercise of stock options.
	A summary of option activity under the plans as of September 30, 2014, and for the nine month period then ended is presented below:
	Options	Number of			Weighted		Weighted		Aggregate
		Shares			Average		Average		Intrinsic
					Exercise		Remaining		Value of
					Price		Contractual		Options
							Term
	Outstanding — January 1, 2014		5,963,478		$	3.66
	Granted		707,816		$	1.35
	Exercised		(467,500	)	$	1.45
	Expired		(812,110	)	$	5.3
	Forfeited		(29,250	)	$	3.73
	Outstanding — September 30, 2014		5,362,434		$	3.31		6.34	$	165,433
	Exercisable — September 30, 2014		3,138,140		$	4.01		4.92	$	18,017
	Vested and Expected to Vest—September 30, 2014		5,260,116		$	3.33		6.3	$	158,652
	There were 467,500 options exercised in the nine month period ended September 30, 2014 and 106,265 in the nine month period ended September 30, 2013.
	Included in the number of options outstanding at September 30, 2014 are 794,186 options with a weighted average exercise price of $5.24 per share and accelerated vesting provisions based on the criteria mentioned above. The total fair value of shares vested during the three and nine month periods ended September 30, 2014 was $0.1 million and $1.9 million, respectively, and was $0.7 million and $0.8 million, respectively, for the three and nine month periods ended September 30, 2013.
	As of January 1, 2014, there were 807,000 shares of restricted stock outstanding under the Plans and during the nine month period ended September 30, 2014, 51,000 shares were forfeited and 256,000 additional shares of restricted stock were granted. The restricted shares vest on various dates between August 15, 2014 and October 29, 2017 and are subject to forfeiture until vested. There were 420,000 shares that vested during the nine month period ended September 30, 2014. The Company recognized $0.5 million and $1.7 million in restricted stock compensation expense during the three and nine month periods ended September 30, 2014, respectively, and recognized $0.3 million and $0.6 million during the three and nine month periods ended September 30, 2013, respectively. As of September 30, 2014, the total compensation cost not yet recognized related to the non-vested restricted stock awards was approximately $0.4 million; this amount is expected to be recognized over a weighted average term of less than one year.

License_Agreements

License Agreements	9 Months Ended
	Sep. 30, 2014
License Agreements	'
	7. License Agreements
	The Company has entered into several nonexclusive license agreements with various companies covering certain technologies which are embedded in the Company’s diagnostic instruments and diagnostic test products. As of September 30, 2014, the Company has paid aggregate initial license fees of $3.7 million for these licenses, and has agreed to pay a percentage of net sales as royalties, in percentage amounts ranging from less than 1.0% to 12.0%. These initial license fees were capitalized as intangible assets (see Note 4). Certain license agreements have minimum annual royalty payments, and such minimum payments are $0.2 million in each of 2014, and 2015 and are less than $0.1 million annually thereafter through the dates the respective licenses terminate. These licenses expire at various times, corresponding to the subject patents expirations, which currently range from 2015 to 2027.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity	'
	8. Stockholders’ Equity
	On September 19, 2014, the Company received a deficiency letter from the Listing Qualifications Department of The NASDAQ Stock Market, notifying the Company that, for the prior 30 consecutive business days, the closing bid price of our common stock was not maintained at the minimum required closing bid price of at least $1.00 per share as required for continued listing on The NASDAQ Global Market. In accordance with NASDAQ Listing Rules, the Company has been given until March 18, 2015 to regain compliance with this requirement.
	On March 18, 2014, the Company entered into a Common Stock Purchase Agreement, or the Purchase Agreement, with Aspire Capital Fund, LLC, or Aspire, to purchase, at our option, up to an aggregate of $30.0 million of shares of our common stock over a two-year term, which expires in March 2016. The Company has not sold any shares under the Purchase Agreement. See Note 10 for discussion on the termination of this agreement October 21, 2014.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies	'
	9. Commitments and Contingencies
	In November 2013, the Company exercised its renewal option on its corporate facility and the lease term was extended to May 2017. Rent and operating expenses associated with the office and laboratory space were $0.2 million and $0.5 million for the three and nine month periods ended September 30, 2014, respectively, and $0.2 million and $0.4 million for the three and nine month periods ended September 30, 2013, respectively.
	Annual future minimum obligations for the operating leases as of September 30, 2014, are as follows (in thousands):
	Years Ending December 31	Operating
		Lease
	2014 (Period from October 1 to December 31)	$	122
	2015		496
	2016		508
	2017		257
	Total minimum lease payments	$	1,383

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events	'
	10. Subsequent Events
	On October 13, 2014, the Company announced that it received 510(k) clearance from the U.S. Food and Drug Administration (the “FDA”) for the Company’s Verigene® Enteric Pathogens Nucleic Acid Test (EP).
	Effective at the close of business on October 21, 2014, the Company terminated the Purchase Agreement with Aspire. No shares of common stock were sold to Aspire Capital under the Purchase Agreement.
	As part of the Company’s efforts to regain compliance with the NASDAQ minimum bid requirements, the listing of the Company’s common stock was transferred from the NASDAQ Global Market to the NASDAQ Capital Market effective October 23, 2014. The Company also has opted-in to NASDAQ’s all inclusive annual listing fee program for 2015.
	On October 27, 2014, the Company completed an underwritten public offering of 40,000,000 shares of its common stock, par value $0.01 per share, at a public offering price of $0.50 per share. As part of the fee payable to the underwriters in connection with the offering, the Company also issued 400,000 shares of common stock to the underwriters. The Company received net proceeds of approximately $18.4 million from the offering after deducting underwriting discounts and commissions and offering expenses. The Company intends to use the net proceeds from the offering for general corporate purposes and working capital.

Supplemental_Financial_Informa

Supplemental Financial Information	9 Months Ended
	Sep. 30, 2014
Supplemental Financial Information	'
	11. Supplemental Financial Information
	Inventories:	September 30, 2014			December 31, 2013
		(in thousands)
	Raw materials	$	3,431		$	2,263
	Work-in-process		314			—
	Finished goods		6,395			6,189
	Total	$	10,140		$	8,452
	Accounts Receivable – Net:	September 30, 2014			December 31, 2013
		(in thousands)
	Accounts Receivable	$	3,352		$	2,821
	Allowance for Doubtful Accounts Receivable		(48	)		—
	Accounts Receivable—net	$	3,304		$	2,821
	Property and Equipment – Net:	September 30, 2014			December 31, 2013
		(in thousands)
	Total property and equipment—at cost	$	24,104		$	21,820
	Less accumulated depreciation		(18,835	)		(18,147	)
	Property and equipment—net	$	5,269		$	3,673
	Other Current Liabilities:	September 30, 2014			December 31, 2013
		(in thousands)
	Accrued clinical trial expenses	$	1,148		$	320
	Accrued license fees		150			84
	All other		1,338			1,130
	Total	$	2,636		$	1,534
		Three months ended September 30,						Nine months ended September 30,
		2014			2013			2014		2013
		(in thousands)						(in thousands)
	Revenues:
	Instruments	$	1,278		$	1,187		$	2,291	$	2,610
	Consumables		2,410			1,180			7,352		3,978
	Total Revenues	$	3,688		$	2,367		$	9,643	$	6,588

Description_of_Business_Polici

Description of Business (Policies)	9 Months Ended
	Sep. 30, 2014
Basis of Presentation	'
	Basis of Presentation — The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and in conformity with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, in the opinion of management, all adjustments, consisting only of normal recurring adjustments, unless otherwise noted herein, necessary to present fairly the results of operations, financial position and cash flows have been made. Therefore, these condensed financial statements should be read in conjunction with the Company’s most recent audited financial statements for the year ended December 31, 2013 and notes thereto included in the Company’s Annual Report on Form 10-K. The results of operations for any interim period are not necessarily indicative of the results of operations expected for the full year.
	The accompanying condensed financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.
Deferred Financing Costs	'
	Deferred Financing Costs— Costs incurred to issue debt are deferred and amortized as a component of interest expense using the effective interest method over the term of the related debt agreement. Amortization expense of deferred financing costs began with the incurrence of the debt in May 2013 and was less than $0.1 million during the three months ended September 30, 2014 and $0.1 million for the nine months ended September 30, 2014. For 2013, deferred financing costs were less than $0.1 million during the three and nine month periods ending September 30, 2013.
Use of Estimates	'
	Use of Estimates — The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company’s significant estimates included in the preparation of the condensed financial statements are related to inventories, property and equipment, intangible assets and share-based compensation. Actual results could differ from those estimates.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments — The carrying amount of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and debt approximate their fair values.
New Accounting Pronouncements	'
	New Accounting Pronouncements — In May 2014, the FASB issued Accounting Standards Update “ASU” No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This new guidance is effective for annual reporting periods beginning on or after December 15, 2016, including interim periods within that reporting period. Early adoption is not permitted. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements.
	In August 2014, the FASB issued ASU No.2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU explicitly requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date. Management will consider relevant conditions that are known (and reasonably knowable) at the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. Disclosures will be required if conditions give rise to substantial doubt. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Early adoption is permitted. The Company currently discloses its uncertainty about its ability to continue as a going concern. The Company does not expect the adoption of ASU No. 2014-15 to have material impact on its disclosures or its consolidated financial statement.

Net_Loss_Per_Common_Share_Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2014
Antidilutive Common Stock and Common Stock Warrants	'
	The computations of diluted net loss per common share for the three and nine month periods ended September 30, 2014 and 2013 did not include the outstanding shares of restricted stock as well as the effects of the following options to acquire common stock and common stock warrants as the inclusion of these securities would have been antidilutive:
		Nine Month Periods Ended September 30,
		2014		2013
	Restricted stock		592,000		478,250
	Restricted stock units		—		220,000
	Stock options		5,362,434		6,068,489
	Common stock warrants		136,019		136,019
			6,090,453		6,902,758

Intangible_Assets_Tables

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Schedule of Intangible Assets, Consisting of Purchased Intellectual Property	'
	Intangible assets, consisting of purchased intellectual property, as of September 30, 2014 and December 31, 2013 comprise the following (in thousands):
		September 30, 2014							December 31, 2013
		Cost		Accumulated			Net		Cost		Accumulated			Net
				Amortization							Amortization
	Intellectual property—licenses	$	3,263	$	(1,363	)	$	1,900	$	3,263	$	(1,152	)	$	2,111
	Patents		455		(194	)		261		455		(160	)		295
		$	3,718	$	(1,557	)	$	2,161	$	3,718	$	(1,312	)	$	2,406
Schedule of Estimated Future Amortization Expense	'
	Estimated future amortization expense is as follows (in thousands):
	Years Ending December 31
	2014 (Period from October 1 to December 31)	$	81
	2015		322
	2016		309
	2017		293
	2018		211
	Thereafter		945

Equity_Incentive_Plan_Tables

Equity Incentive Plan (Tables)	9 Months Ended
	Sep. 30, 2014
Assumptions Used Fair Value of Option Awards Granted Using Black-Scholes Option Pricing Model	'
	The fair values of the Company’s option awards granted during the nine month period ended September 30, 2014 were estimated at the dates of grant using the Black-Scholes option pricing model with the following assumptions:
	Expected dividend yield		0	%
	Expected volatility		78	%
	Risk free interest rate		1.78	%
	Weighted-average expected option life in years		5.51
	Estimated weighted-average fair value on the date of grant based on the above assumptions	$	0.88
	Estimated forfeiture rate for unvested options		0	%
Summary of Option Activity	'
	A summary of option activity under the plans as of September 30, 2014, and for the nine month period then ended is presented below:
	Options	Number of			Weighted		Weighted		Aggregate
		Shares			Average		Average		Intrinsic
					Exercise		Remaining		Value of
					Price		Contractual		Options
							Term
	Outstanding — January 1, 2014		5,963,478		$	3.66
	Granted		707,816		$	1.35
	Exercised		(467,500	)	$	1.45
	Expired		(812,110	)	$	5.3
	Forfeited		(29,250	)	$	3.73
	Outstanding — September 30, 2014		5,362,434		$	3.31		6.34	$	165,433
	Exercisable — September 30, 2014		3,138,140		$	4.01		4.92	$	18,017
	Vested and Expected to Vest—September 30, 2014		5,260,116		$	3.33		6.3	$	158,652

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2014
Annual Future Minimum Obligations for Operating Leases	'
	Annual future minimum obligations for the operating leases as of September 30, 2014, are as follows (in thousands):
	Years Ending December 31	Operating
		Lease
	2014 (Period from October 1 to December 31)	$	122
	2015		496
	2016		508
	2017		257
	Total minimum lease payments	$	1,383

Supplemental_Financial_Informa1

Supplemental Financial Information (Tables)	9 Months Ended
	Sep. 30, 2014
Inventories	'
	Inventories:	September 30, 2014			December 31, 2013
		(in thousands)
	Raw materials	$	3,431		$	2,263
	Work-in-process		314			—
	Finished goods		6,395			6,189
	Total	$	10,140		$	8,452
Accounts Receivable Net	'
	Accounts Receivable – Net:	September 30, 2014			December 31, 2013
		(in thousands)
	Accounts Receivable	$	3,352		$	2,821
	Allowance for Doubtful Accounts Receivable		(48	)		—
	Accounts Receivable—net	$	3,304		$	2,821
Property and Equipment-Net	'
	Property and Equipment – Net:	September 30, 2014			December 31, 2013
		(in thousands)
	Total property and equipment—at cost	$	24,104		$	21,820
	Less accumulated depreciation		(18,835	)		(18,147	)
	Property and equipment—net	$	5,269		$	3,673
Other Current Liabilities	'
	Other Current Liabilities:	September 30, 2014			December 31, 2013
		(in thousands)
	Accrued clinical trial expenses	$	1,148		$	320
	Accrued license fees		150			84
	All other		1,338			1,130
	Total	$	2,636		$	1,534
Revenues	'
		Three months ended September 30,						Nine months ended September 30,
		2014			2013			2014		2013
		(in thousands)						(in thousands)
	Revenues:
	Instruments	$	1,278		$	1,187		$	2,291	$	2,610
	Consumables		2,410			1,180			7,352		3,978
	Total Revenues	$	3,688		$	2,367		$	9,643	$	6,588

Description_of_Business_Additi

Description of Business - Additional Information (Detail) (USD $)	9 Months Ended	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2013
		Maximum	Maximum	Maximum
Organization Consolidation And Presentation Of Financial Statements [Line Items]	'	'	'	'
Amortization of deferred financing costs	$0.10	$0.10	$0.10	$0.10

Liquidity_and_Capital_Resource1

Liquidity and Capital Resources - Additional Information (Detail) (USD $)	9 Months Ended					0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	6-May-13	Dec. 31, 2012	Mar. 18, 2014
						Aspire Capital Fund LLC
Subsidiary, Sale of Stock [Line Items]	'	'	'	'	'	'
Net losses attributable to common stock since inception	($412,500,000)	'	'	'	'	'
Cash and cash equivalents	12,507,000	49,264,000	41,467,000	'	33,139,000	'
Net cash used in operating activities	-26,291,000	-26,624,000	'	'	'	'
Debt facility, agreement amount	'	'	'	22,000,000	'	'
Debt facility, outstanding amount	'	'	'	12,000,000	'	'
Common stock purchase agreement, maximum authorized amount	'	'	'	'	'	$30,000,000
Common stock purchase agreement, term	'	'	'	'	'	'2 years
Sales of common stock	'	'	'	'	'	0

Net_Loss_Per_Common_Share_Addi

Net Loss Per Common Share - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Shares excluded from computation of basic net loss per common share	'	'	6,090,453	6,902,758
Restricted stock	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Shares excluded from computation of basic net loss per common share	592,000	478,250	592,000	478,250

Net_Loss_Per_Common_Share_Deta

Net Loss Per Common Share (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive common stock and common stock warrants	'	'	6,090,453	6,902,758
Restricted stock	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive common stock and common stock warrants	592,000	478,250	592,000	478,250
Restricted stock units	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive common stock and common stock warrants	'	'	'	220,000
Stock options	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive common stock and common stock warrants	'	'	5,362,434	6,068,489
Common stock warrants	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive common stock and common stock warrants	'	'	136,019	136,019

Intangible_Assets_Detail

Intangible Assets (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	$3,718	$3,718
Accumulated Amortization	-1,557	-1,312
Net	2,161	2,406
Intellectual property - licenses	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	3,263	3,263
Accumulated Amortization	-1,363	-1,152
Net	1,900	2,111
Patents	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	455	455
Accumulated Amortization	-194	-160
Net	$261	$295

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization expense for intangible assets	$0.10	$0.10	$0.20	$0.20

Estimated_Future_Amortization_

Estimated Future Amortization Expenses (Detail) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Schedule Of Estimated Future Amortization Expense [Line Items]	'
2014 (Period from October 1 to December 31)	$81
2015	322
2016	309
2017	293
2018	211
Thereafter	$945

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (Dr. Chad Mirkin, Research and Development Expense, Maximum, USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Dr. Chad Mirkin | Research and Development Expense | Maximum	'
Related Party Transaction [Line Items]	'
Related party transaction, expenses incurred	$0.10

Equity_Incentive_Plan_Addition

Equity Incentive Plan - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

In Millions, except Share data, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Jan. 01, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Restricted stock

Restricted stock

Equity Incentive Plan 2000

Minimum

Minimum

Maximum

Maximum

Maximum

Upon achievement of each of four or five milestones

Upon achievement of each of four or five milestones

Restricted stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Option awards contractual terms

'

'

'

'

'

'

'10 years

'

'

'

'

'

Accelerated vesting options

'

'

'

'

'

'

'

'

20.00%

'

25.00%

'

Equity awards, vesting period

'

'

'

'

'

'

'

'4 years

'

'7 years

'

'

Percentage of options granted and outstanding with accelerated vesting provisions

'

'

15.00%

'

'

'

'

'

'

'

'

'

Total compensation cost associated with option awards

$0.80

$0.40

$2.60

$1.10

'

'

'

'

'

'

'

'

Total compensation cost not yet recognized

2

'

2

'

'

'

'

'

'

'

'

'

Unrecognized share based compensation recognition period

'

'

'3 years

'

'

'

'

'

'

'

'

'1 year

Milestone vesting term

'

'

'7 years

'

'

'

'

'

'

'

'

'

Weighted average term remains

'

'

'1 year 8 months 12 days

'

'

'

'

'

'

'

'

'

Options exercised

'

'

467,500

106,265

'

'

'

'

'

'

'

'

Number of Options Outstanding with accelerated vesting provisions

794,186

'

794,186

'

'

'

'

'

'

'

'

'

Weighted average exercise options with accelerated vesting provisions

$5.24

'

$5.24

'

'

'

'

'

'

'

'

'

Total fair value of shares, vested

0.1

0.7

1.9

0.8

'

'

'

'

'

'

'

'

Restricted stock, outstanding

'

'

'

'

'

807,000

'

'

'

'

'

'

Restricted stock, forfeited

'

'

51,000

'

'

'

'

'

'

'

'

'

Restricted stock, granted

'

'

'

'

256,000

'

'

'

'

'

'

'

Restricted stock, vested

'

'

420,000

'

'

'

'

'

'

'

'

'

Restricted stock compensation expense

0.5

0.3

1.7

0.6

'

'

'

'

'

'

'

'

Total compensation cost not yet recognized, non-vested restricted stock

'

'

'

'

$0.40

'

'

'

'

'

'

'

Assumptions_Used_for_Fair_Valu

Assumptions Used for Fair Value of Option Awards Granted Using Black-Scholes Option Pricing Model (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Expected dividend yield	0.00%
Expected volatility	78.00%
Risk free interest rate	1.78%
Weighted-average expected option life in years	'5 years 6 months 4 days
Estimated weighted-average fair value on the date of grant based on the above assumptions	$0.88
Estimated forfeiture rate for unvested options	0.00%

Summary_of_Option_Activity_Det

Summary of Option Activity (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Number of Shares	'	'
Outstanding - January 1, 2014	5,963,478	'
Granted	707,816	'
Exercised	-467,500	-106,265
Expired	-812,110	'
Forfeited	-29,250	'
Outstanding - September 30, 2014	5,362,434	'
Exercisable - September 30, 2014	3,138,140	'
Vested and Expected to Vest-September 30, 2014	5,260,116	'
Weighted Average Exercise Price	'	'
Outstanding - January 1, 2014	$3.66	'
Granted	$1.35	'
Exercised	$1.45	'
Expired	$5.30	'
Forfeited	$3.73	'
Outstanding - September 30, 2014	$3.31	'
Exercisable - September 30, 2014	$4.01	'
Vested and Expected to Vest-September 30, 2014	$3.33	'
Weighted Average Remaining Contractual Term	'	'
Outstanding - September 30, 2014	'6 years 4 months 2 days	'
Exercisable - September 30, 2014	'4 years 11 months 1 day	'
Vested and Expected to Vest-September 30, 2014	'6 years 3 months 18 days	'
Aggregate Intrinsic Value of Options	'	'
Outstanding - September 30, 2014	$165,433	'
Exercisable - September 30, 2014	18,017	'
Vested and Expected to Vest-September 30, 2014	$158,652	'

License_Agreements_Additional_

License Agreements - Additional Information (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Finite-Lived Intangible Assets [Line Items]	'
License fees	3.7
Minimum annual royalty payments, 2014	0.2
Minimum annual royalty payments, 2015	0.2
Minimum	'
Finite-Lived Intangible Assets [Line Items]	'
Royalty percentage paid	1.00%
License agreement, expiration date	'2015
Maximum	'
Finite-Lived Intangible Assets [Line Items]	'
Royalty percentage paid	12.00%
Minimum annual royalty payments, thereafter	0.1
License agreement, expiration date	'2027

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	0 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 19, 2014	Mar. 18, 2014	Sep. 19, 2014
		Aspire Capital Fund LLC	Minimum
Class of Warrant or Right [Line Items]	'	'	'
Closing bid price	'	'	$1
Number of prior business days which closing bid price of common stock not maintained	'30 days	'	'
Date of regain compliance with stock market requirement	18-Mar-15	'	'
Common stock purchase agreement, maximum authorized amount	'	$30	'
Common stock purchase agreement, term	'	'2 years	'
Common stock purchase agreement, expiration date	'	'2016-03	'
Sales of common stock	'	0	'

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Commitment And Contingencies [Line Items]	'	'	'	'
Rent and operating expenses associated with office and laboratory space	$0.20	$0.20	$0.50	$0.40

Annual_Future_Minimum_Obligati

Annual Future Minimum Obligations for Operating Leases (Detail) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Schedule of Operating Leases [Line Items]	'
2014 (Period from October 1 to December 31)	$122
2015	496
2016	508
2017	257
Total minimum lease payments	$1,383

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (USD $)	9 Months Ended			0 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013	Mar. 18, 2014	Oct. 21, 2014	Oct. 27, 2014	Oct. 27, 2014
				Aspire Capital Fund LLC	Subsequent Event	Subsequent Event	Subsequent Event
					Aspire Capital Fund LLC	Underwritten Public Offering	Underwritten Public Offering
Subsequent Event [Line Items]	'	'	'	'	'	'	'
Sales of common stock	'	'	'	0	0	40,000,000	'
Common stock, par value	'	$0.01	$0.01	'	'	'	$0.01
Issuance of common stock as a fee payable to underwriters	'	'	'	'	'	400,000	'
Common stock price per share	'	'	'	'	'	'	$0.50
Proceeds from the issuance of common stock, net of offering expenses	$32,630	'	'	'	'	$18,400	'

Inventories_Detail

Inventories (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Supplemental Financial Information [Line Items]	'	'
Raw materials	$3,431	$2,263
Work-in-process	314	'
Finished goods	6,395	6,189
Total	$10,140	$8,452

Accounts_Receivable_Net_Detail

Accounts Receivable Net (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Supplemental Financial Information [Line Items]	'	'
Accounts Receivable	$3,352	$2,821
Allowance for Doubtful Accounts Receivable	-48	'
Accounts Receivable-net	$3,304	$2,821

Property_and_EquipmentNet_Deta

Property and Equipment-Net (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment-at cost	$24,104	$21,820
Less accumulated depreciation	-18,835	-18,147
Property and equipment-net	$5,269	$3,673

Other_Current_Liabilities_Deta

Other Current Liabilities (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Supplemental Financial Information [Line Items]	'	'
Accrued clinical trial expenses	$1,148	$320
Accrued license fees	150	84
All other	1,338	1,130
Total	$2,636	$1,534

Revenues_Detail

Revenues (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue from External Customer [Line Items]	'	'	'	'
Total revenue	$3,688	$2,367	$9,643	$6,588
Instruments	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Total revenue	1,278	1,187	2,291	2,610
Consumables	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Total revenue	$2,410	$1,180	$7,352	$3,978